Recent advances toward the clinical application of PTH (1-34) in fracture healing

Cara A. Cipriano, Paul S. Issack, Lisa Shindle, Clément M.L. Werner, David L. Helfet, Joseph M. Lane

Research output: Contribution to journalArticlepeer-review

31 Scopus citations


PTH 1-34, an active form of parathyroid hormone, has been shown to enhance osteoblastic bone formation when administered as a daily subcutaneous injection. The effect of the intermittent administration of PTH (1-34) is an uncoupling of bone turnover with an increase in bone mass and density and decrease in risk of vertebral and nonvertebral fractures. While PTH (1-34) has been used clinically to increase bone mass and reduce fracture risk in postmenopausal women with osteoporosis, there is increasing evidence that PTH (1-34) may promote fracture healing. Animal studies have demonstrated accelerated callus formation with enhanced remodeling and biomechanical properties of the healing fracture. Given these effects, PTH (1-34) will likely be used clinically to enhance fracture union in poor healing situations such as osteoporosis and recalcitrant nonunions.

Original languageEnglish
Pages (from-to)149-153
Number of pages5
JournalHSS Journal
Issue number2
StatePublished - Sep 2009


Dive into the research topics of 'Recent advances toward the clinical application of PTH (1-34) in fracture healing'. Together they form a unique fingerprint.

Cite this